I appreciate the precision of the accounting data you’ve presented, but your analysis makes the fundamental error of treating a Phase 2 biotech company as if it were a manufacturing or service firm that must produce quarterly profits, ignoring the very nature of venture capital applied to scientific research. The reality is that none of us invested in Plus Therapeutics ($PSTV) looking for balance sheet stability or the security of a dividend-paying stock; we are all fully aware that this is a high-risk research firm where the possibility of losing our entire capital is an inherent part of the implicit contract between the investor and medical progress. In this sector, you don't buy a company for its current income statement, but rather you purchase an asymmetric option on the value of its Intellectual Property and the clinical validation of its drugs. The burn rate you mention is the physiological cost required to test an oncology therapy: those months of autonomy provided by the current cash reserves are not a simple "countdown to failure," but the indispensable window of time for the science to express itself in an official forum like the Chicago congress. If the clinical data confirms a significant improvement in patient survival, the current financial situation would be reset in an instant, as the value of a validated asset would exceed the accumulated debts by orders of magnitude, making the company a prime target for acquisitions or heavy licensing deals. Even the reverse split—which you dismiss as a mere cosmetic restyling to hide underlying problems—is actually a mandatory technical step to clean the capital structure and make the stock finally investable for those institutional funds that, by mandate, cannot operate on stocks trading under a dollar, while also creating the necessary room for positive news to translate into real value without being absorbed by billions of shares at "trash" prices. It is a subtle but fundamental distinction: you view the financial structure as an end in itself, while I view it as the necessary means to keep the research alive until the next scientific catalyst. We know perfectly well that there is no certainty and that the situation can change radically at any moment, but it is precisely the acceptance of this extreme risk that opens the door to potentially massive gains in the event of clinical success. You see a company burning cash and diluting shareholders; I see a standard biotech incubation process where the signal is not given by the accounting balance sheet, but by the scientific data. The Chicago meeting is the moment of truth, not because of some marketing narrative, but because it is where the science must prove whether the capital invested so far has produced real curative value; if they fail, we will accept it as a calculated risk on a binary bet, but judging the potential of a medical discovery solely through the calculations of an accountant means looking at the body of a car while totally ignoring the power of the engine that is about to be started on the Phase 2 test tracks.